SCYNEXIS, Inc. (SCYX)

SCYNEXIS, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

SCYNEXIS, Inc. (SCYX) is a Drug Manufacturers - Specialty & Generic company based in US with a market capitalization of $37.7M. Revenue grew 449.9% year-over-year and free cash flow was negative at -$5.3M. This page tracks SCYX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 28 employees · IPO May 2, 2014

Valuation

Valuation & price

$0.74as of May 17, 2026· -92.2% vs 52w high

P/E ratio

Latest-FY diluted EPS

0.76

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$9.44$6.62$3.80Jul 25Dec 25Jul 26
$3.8052-week range$9.44
Loading valuation history…

Fundamentals

Key fundamentals

$37.7M

Market cap

449.9%

Revenue growth (YoY)

100.0%

Gross margin

-$5.3M

Free cash flow (USD)

-$19.1M

Net debt

Net cash position

2.9%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$257K$20.6M

Free cash flow by year

20162025

-$29.4M-$5.3M

Gross margin by year

20212025

97.6%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 26, 2026Filing

    Authorized Shares Increase

  • 8-K eventMay 29, 2026Filing

    Reverse Stock Split

  • 8-K eventMay 22, 2026Filing

    Reverse Stock Split

  • Quarterly reportMay 11, 2026Filing

    10-Q Filed

  • FinancingMay 1, 2026Filing

    Securities Registration

  • 8-K eventApr 20, 2026Filing

    Director Retirement

Questions

Frequently asked questions

What is SCYNEXIS, Inc.'s market cap?

SCYNEXIS, Inc. (SCYX) has a market capitalization of $37.7M.

What is SCYX's P/E ratio?

A meaningful P/E ratio is not available for SCYX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is SCYX's price-to-book (P/B) ratio?

SCYX trades at 0.76 times book value per share.

Are insiders buying SCYX stock?

SEC Form 4 filings show no open-market insider buys at SCYNEXIS, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Drug Manufacturers - Specialty & Generic

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.